Get the Stockscreener App
2.47
1.59%
-0.04
Codexis Inc stock is traded at $2.47, with a volume of 586.32K.
It is down -1.59% in the last 24 hours and up +16.51% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.51
Open:
$2.56
24h Volume:
586.32K
Relative Volume:
0.68
Market Cap:
$204.64M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-2.2252
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
+0.41%
1M Performance:
+16.51%
6M Performance:
-36.34%
1Y Performance:
-34.48%
1-Day Range:
$2.378
$2.575
1-Week Range:
$1.95
$2.70
52-Week Range:
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.47 | 203.80M | 70.14M | -76.24M | -57.06M | -1.11 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Codexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Call Transcript - Insider Monkey
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Stifel Financial Corp - Defense World
Codexis reiterates $64M-$68M 2025 revenue guidance as ecosynthesis platform gains traction with CDMOs - MSN
Stifel maintains Buy rating on Codexis stock with $5 target By Investing.com - Investing.com India
Stifel maintains Buy rating on Codexis stock with $5 target - Investing.com Australia
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with Strategic Growth Initiatives - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings: EPS at -$0.23 and Revenue H - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... - Yahoo Finance
Codexis Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Codexis: Q1 Earnings Snapshot - MySA
Earnings call transcript: Codexis Q1 2025 results miss forecasts, stock declines - Investing.com Nigeria
Codexis (CDXS) Navigates Q1 Revenue Challenges, Confirms 2025 Ou - GuruFocus
Codexis, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Projects Financial Stability Until 2026 | CDXS St - GuruFocus
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Codexis (CDXS) Reports Lower Than Expected Q1 Revenue, Affirms 2 - GuruFocus
Codexis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Codexis May 2025 presentation slides: RNA manufacturing pivot targets path to profitability - Investing.com Australia
CODEXIS Earnings Results: $CDXS Reports Quarterly Earnings - Nasdaq
Codexis (CDXS) Reports Lower Than Expected Q1 Revenue, Affirms 2025 Outlook | CDXS Stock News - GuruFocus
Codexis Reports First Quarter 2025 Financial Results - TradingView
Codexis Secures Landmark ECO Synthesis Deal as Q1 Earnings Show Strategic Pivot to RNA Manufacturing - Stock Titan
Thinking Of Selling Codexis Inc (NASDAQ: CDXS) Stock? Check This Out First - Stocksregister
MetLife Investment Management LLC Increases Holdings in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Wells Fargo & Company MN - Defense World
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Codexis, Inc. (NASDAQ: CDXS) and Encourages CDXS Shareholders to Contact the Firm - ACCESS Newswire
Financial Metrics Exploration: Understanding Codexis Inc (CDXS) Through Ratios - DWinneX
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting - GlobeNewswire
Codexis, Inc. (NASDAQ:CDXS) Stake Increased by Barclays PLC - Defense World
Recent uptick might appease Codexis, Inc. (NASDAQ:CDXS) institutional owners after losing 36% over the past year - simplywall.st
Top 5 Synthetic Biology Public Companies (May 2025) - Securities.io
BlackRock, Inc. Reduces Stake in Codexis Inc. - GuruFocus
Codexis to Report First Quarter 2025 Financial Results on May 14 - The Manila Times
Codexis, Inc. to Release First Quarter 2025 Financial Results on May 14, 2025 - Nasdaq
Codexis Q1 2025 Earnings Call: Key Details for Investors RevealedMark Your Calendar - Stock Titan
Opaleye Management Makes Strategic Move with Codexis Stock Purchase - TipRanks
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by JPMorgan Chase & Co. - Defense World
Envestnet Asset Management Inc. Purchases 110,541 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Codexis Inc (CDXS) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocksregister
Codexis, Inc. (NASDAQ:CDXS) Holdings Decreased by Russell Investments Group Ltd. - Defense World
Codexis Inc [CDXS] Shares Rise 2.24 % on Wednesday - knoxdaily.com
Codexis Inc (CDXS) stock analysis: A comprehensive overview - uspostnews.com
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Geode Capital Management LLC Boosts Stock Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (CDXS) to Release Quarterly Earnings on Thursday - The AM Reporter
Codexis (CDXS) Projected to Post Earnings on Thursday - Defense World
Quarterly Snapshot: Quick and Current Ratios for Codexis Inc (CDXS) - DWinneX
Global Biocatalysis Market Growth Trends & Insights2024-2031 - openPR.com
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
May 01 '25 |
Buy |
2.32 |
20,000 |
46,436 |
9,675,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 25 '25 |
Buy |
2.24 |
25,000 |
55,915 |
9,630,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 16 '25 |
Buy |
2.13 |
70,000 |
148,890 |
9,560,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 17 '25 |
Buy |
2.09 |
45,000 |
94,162 |
9,605,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 15 '25 |
Buy |
2.23 |
25,000 |
55,720 |
9,490,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 08 '25 |
Buy |
1.98 |
100,000 |
198,380 |
9,465,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 03 '25 |
Buy |
2.30 |
75,000 |
172,740 |
9,365,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 01 '25 |
Buy |
2.48 |
35,000 |
86,772 |
9,285,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 02 '25 |
Buy |
2.46 |
5,000 |
12,276 |
9,290,000 |
| Opaleye Management Inc. | 10% Owner |
Mar 21 '25 |
Buy |
2.54 |
92,923 |
236,266 |
9,250,000 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):